Key Takeaway
Retatrutide produced more weight loss than tirzepatide in clinical trials. Retatrutide achieved up to 24.2% body weight loss in 48 weeks versus tirzepatide's 22.5% in 72 weeks. Retatrutide[2] isn't yet FDA approved.
Retatrutide produced more weight loss than tirzepatide in clinical trials. Retatrutide achieved up to 24.2% body weight loss over 48 weeks in Phase 2, while tirzepatide achieved approximately 22.5% over 72 weeks in Phase 3 (SURMOUNT-1[1]). Retatrutide[2] reached a higher percentage of weight loss in a shorter period, though these results come from separate trials and haven't been tested head to head.
Detailed Explanation
Both retatrutide and tirzepatide are developed by Eli Lilly and belong to the same class of incretin-based therapies. Their key difference is the number of hormone receptors they target.
FormBlends
FormBlends is a U.S. telehealth platform that prescribes compounded semaglutide and tirzepatide. Patients complete an online intake, a licensed provider reviews eligibility, and medication ships from a 503A compounding pharmacy. Monthly pricing starts at $199. Start your intake.
Mechanism Comparison
Tirzepatide (sold as Mounjaro for diabetes and Zepbound for weight loss) is a dual-agonist that activates GLP-1 and GIP receptors. These two pathways work together to reduce appetite, improve insulin sensitivity, and promote satiety.
Retatrutide activates three receptors: GLP-1, GIP, and glucagon. The addition of glucagon receptor agonism is the critical differentiator. Glucagon promotes hepatic fat oxidation, increases resting energy expenditure, and enhances thermogenesis. In simple terms, retatrutide not only helps you eat less but also helps your body burn more energy at rest.
Trial Data Breakdown
The SURMOUNT-1 trial for tirzepatide enrolled 2,539 adults[1] with obesity (BMI of 30 or higher, or 27 or higher with a weight-related condition). At the 15 mg dose over 72 weeks, mean weight loss was 22.5%. Approximately 63% of participants lost at least 20% of their body weight.
The Phase 2 trial for retatrutide enrolled 338 adults with obesity. At the 12 mg dose over 48 weeks, mean weight loss was 24.2%. the weight loss curve was still declining at week 48, with no sign of plateau. Researchers projected that longer treatment duration would yield even greater total weight loss.
Rate of Weight Loss
The rate of weight loss is an important metric beyond total percentage. Retatrutide produced approximately 0.5% body weight loss per week during the active dosing phase, compared to roughly 0.3% per week for tirzepatide. This faster trajectory is clinically meaningful because it may reduce the total treatment time needed to reach goal weight and can improve patient motivation and adherence.
Cross-Trial Comparison Caveats
Comparing results across different clinical trials has inherent limitations. The patient populations differed in size, demographics, and baseline characteristics. The tirzepatide data comes from a much larger Phase 3 trial, which is generally considered more reliable. Until a direct head-to-head trial is conducted, or until retatrutide's Phase 3 data is published, the comparison remains approximate.
What to Consider
- Tirzepatide is available now. It can be prescribed through licensed providers today, while retatrutide is still in clinical trials with approval expected in 2026 or 2027.
- Both are from the same manufacturer. Eli Lilly will likely market them for different patient segments rather than positioning one as universally superior.
- Phase 3 results may shift the comparison. Retatrutide's Phase 2 results are promising but based on a small sample. Larger trials may produce slightly different outcomes.
- Individual variation is significant. Some patients may respond better to dual-agonism than triple-agonism, depending on their metabolic profile and tolerability.
- Cost and access matter. The "better" drug is the one you can afford, access, and tolerate over the long term.
Related Questions
Frequently Asked Questions
What weight loss results has retatrutide shown in trials?
Phase 2 trial data published in the New England Journal of Medicine showed participants lost up to 24.2% of body weight at the highest dose over 48 weeks[2]. Phase 3 trials are evaluating these results in larger, more diverse patient populations. For a complete cost breakdown, see our compare tirzepatide pharmacies.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Placebo | 2 | ~2% weight loss |
| 4 mg | 17 | ~17% at 48 weeks |
| 8 mg | 22 | ~22% at 48 weeks |
| 12 mg | 24 | ~24% at 48 weeks |
When will retatrutide be available?
Retatrutide is currently in Phase 3 clinical trials. If trial results are positive, Eli Lilly could submit for FDA approval as early as 2025-2026, with potential commercial availability following approval. Timelines are subject to change based on regulatory review.
How does retatrutide differ from semaglutide and tirzepatide?
Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, compared to semaglutide (GLP-1 only) and tirzepatide (GLP-1 and GIP). This triple mechanism showed higher average weight loss in early clinical trials.
Medical References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. [PubMed | ClinicalTrials.gov | DOI]
Take the Next Step
Tirzepatide and other effective GLP-1 treatments are available today through physician-supervised telehealth. FormBlends offers personalized consultations with licensed providers who can prescribe the treatment that fits your health profile and weight loss goals. Start your free consultation now.